Robert W. Baird Cuts IQVIA (NYSE:IQV) Price Target to $212.00

IQVIA (NYSE:IQV) had its price objective decreased by Robert W. Baird from $213.00 to $212.00 in a research note released on Wednesday,Benzinga reports. Robert W. Baird currently has a neutral rating on the medical research company’s stock.

Other equities research analysts have also issued research reports about the stock. Evercore ISI cut their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. BTIG Research reduced their price target on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a report on Friday, November 1st. JPMorgan Chase & Co. dropped their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th. Royal Bank of Canada restated an “outperform” rating and set a $270.00 target price on shares of IQVIA in a report on Wednesday, December 4th. Finally, Leerink Partners reiterated an “outperform” rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $256.19.

IQVIA Stock Performance

NYSE:IQV opened at $199.06 on Wednesday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. IQVIA has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The business has a 50 day moving average price of $212.24 and a 200-day moving average price of $224.23. The firm has a market cap of $36.13 billion, a PE ratio of 26.12, a price-to-earnings-growth ratio of 2.07 and a beta of 1.49.

Institutional Investors Weigh In On IQVIA

Hedge funds have recently added to or reduced their stakes in the stock. Simplify Asset Management Inc. raised its position in shares of IQVIA by 67.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares during the last quarter. Raymond James & Associates raised its holdings in IQVIA by 0.7% in the second quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock worth $169,231,000 after buying an additional 5,417 shares during the last quarter. Versor Investments LP bought a new position in shares of IQVIA in the third quarter worth approximately $1,328,000. Gradient Investments LLC grew its holdings in shares of IQVIA by 15.6% during the second quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company’s stock valued at $9,600,000 after buying an additional 6,134 shares during the last quarter. Finally, CIBC Asset Management Inc raised its holdings in IQVIA by 3.3% in the 3rd quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock worth $62,501,000 after acquiring an additional 8,490 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.